Screener
Entrada Therapeutics TRDA Q3 2025 earnings
Reported November 6, 2025 · Before market open
Revenue$1.6MMiss by $6.9M
EPS-$1.06Miss by $0.02
Revenue estimate$8.5M
EPS estimate-$1.04
Next report
Nov 5, 2026 (in 2 months)Revenue estimate$2.1M
EPS estimate-$0.98
Versus estimates
Revenue
Diluted EPS
FAQ
- When did Entrada Therapeutics report Q3 2025 earnings?
- Entrada Therapeutics (TRDA) reported Q3 2025 earnings on November 6, 2025 before market open.
- What were Entrada Therapeutics's Q3 2025 revenue and EPS?
- Entrada Therapeutics reported revenue of $1.6M and eps of $-1.06 for Q3 2025.
- Did Entrada Therapeutics beat estimates in Q3 2025?
- Revenue missed the consensus estimate of $8.5M by $6.9M. EPS missed the consensus estimate of $-1.04 by $0.02.
- How did Entrada Therapeutics's Q3 2025 results compare year-over-year?
- Compared to the same quarter a year prior, revenue declined 91.8% from $19.6M a year earlier and eps declined 202.9% from $-0.35.
- Where can I find Entrada Therapeutics's Q3 2025 SEC filings?
- You can read the 8-K earnings release (0001689375-25-000049) and the 10-Q periodic report (0001689375-25-000050) directly on SEC EDGAR. The filing index links above go to sec.gov.
